Improving treatments for organophosphate poisoning
Optimization of Substituted Phenoxyalkyl Pyridinium Oximes as Therapies for Organophosphate Poisoning
This study is looking for better treatments for people who have been poisoned by certain toxic chemicals, aiming to create a new medicine that can help protect the brain and improve recovery after exposure.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mississippi State University NIH-funded |
| Lab location | 1 site (Mississippi State, United States) |
| Project ID | NIH-10906087 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for organophosphate poisoning, which can occur from exposure to toxic nerve agents. Current treatments, like atropine and 2-PAM, are not always effective, especially in protecting the brain. The study aims to create a new type of oxime that can better penetrate the blood-brain barrier and improve survival rates and neurological outcomes in affected individuals. The research involves testing these new compounds in animal models to assess their effectiveness and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals who have been exposed to organophosphate compounds, such as those involved in accidents or terrorist attacks.
Not a fit: Patients who have not been exposed to organophosphate compounds are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for organophosphate poisoning, potentially saving lives and preserving brain function.
How similar studies have performed: Previous studies have shown that similar approaches using new oxime compounds have improved outcomes in animal models, indicating potential for success in this research.
Where this research is happening
Mississippi State, United States
- Mississippi State University — Mississippi State, United States (Active)
Researchers
- Principal investigator: Chambers, Janice Elaine — Mississippi State University
- Study coordinator: Chambers, Janice Elaine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.